The use of the peroxisome proliferator-activated receptor-c (PPAR-c) agonist pioglitazone, which is registered as an oral antidiabetic drug, has consistently been associated with a decrease in blood pressure (BP) of about 3-5 mm Hg. The present study evaluates the effects of pioglitazone treatment on circulating levels of vasoactive factors in a randomized controlled crossover trial in patients with type II diabetes (T2DM). We here report that pioglitazone does not alter the circulating levels of renin, prorenin, angiotensin II, aldosterone, endothelin, atrial and brain natriuretic peptide (ANP, BNP) and semicarbazide-sensitive amine oxidase (SSAO). Effects of pioglitazone on BP (or cardiovascular events) are likely to be mediated through other mechanisms.
Activation of the PPAR-g leads to hypoglycaemic and hypolipidaemic effects. Therefore, potent synthetic ligands called thiazolidinediones (TZDs, like pioglitazone and rosiglitazone) have been developed and are currently used as glucose-lowering agents in the treatment of T2DM.
Besides their established glucose-lowering effects, PPAR-g agonists have supposedly ancillary effects, most notably beneficial effects on inflammatory status and lipid profile, but also by direct beneficial effects on the vasculature. 1 Specifically, TZDs reduce BP, with evidence for a direct vascular effect involving decreased calcium uptake into vascular cells. Furthermore, several animal and human studies have shown that BP lowering by TZDs is associated with decreased insulin levels and improvement of endothelial function. 2, 3 In large-scale outcome trials with TZDs, pioglitazone showed a small but significant reduction in systolic BP compared to placebo (median change in systolic BP 3 mm Hg versus 0 mm Hg), with a reduction of major cardiovascular events in the PROactive trial. 4 In addition, when added to metformin or a sulfonylurea, a 12-month treatment with rosiglitazone reduces ambulatory BP to a greater extent than when metformin and a sulfonylurea are combined (median change in BP 2.5 mm Hg systolic and 3.1 mm Hg diastolic), as shown in a substudy of the RECORD trial. 5 Overall it is suggested that TZDs reduce BP by 4-5 mm Hg systolic and 2-4 mm Hg diastolic. 6 In summary, there are interesting concepts suggested about direct vascular effects of TZDs, which are not yet completely understood. Particularly, the paradox of TZD-induced decrease in BP accompanied by an increase in the plasma volume has not been fully explained yet.
Therefore in this randomized placebo-controlled, crossover study, 7, 8 we evaluated the effects of pioglitazone on the plasma concentrations of vasoactive peptides and hormones in patients with T2DM.
The protocol was approved by the ethical review board of the University Medical Center Utrecht, the Netherlands. All subjects gave written informed consent. Twenty male, non-smoking patients with T2DM were recruited. All patients used oral glucoselowering agents (sulfonylurea derivatives, metformin or a combination of both), which were continued during the study. The baseline and demographic characteristics of all patients were previously described. 7, 8 Relevant exclusion criteria were presence of macro-or microvascular disease and use of vasoactive medication (for example, b-blockers, calcium entry blockers, ACE inhibitors, angiotensin type 1 receptor blockers, statins, aspirin or nonsteroidal inflammatory drugs). The study was a prospective, randomized, crossover, placebo-controlled, double-blind trial. Patients were randomized to pioglitazone (30 mg once daily, supplied by Eli Lilly, the Netherlands) or placebo for 4 weeks. Crossover of therapy occurred at the end of the washout period (6 weeks). At the beginning and at the end of each 4-week treatment period, laboratory parameters were determined. Patients were instructed to fast for at least 10 h before the tests. No study medication or other medication was used on the morning of the study days.
Fasting blood was drawn, and plasma was frozen at À20 1C until further analysis. Protocols for standard haematology and chemistry have been described. 7 Plasma renin activity (PRA; ng ml À1 h
À1
) was determined by in-house radioimmunoassay of generated angiotensin I; prorenin (ng ml À1 h
) was measured in the same assay after prior conversion of prorenin to renin by Sepharose-bound trypsin. S1 Angiotensin II (pmol l À1 ) was determined after SepPak extraction from plasma with a specific in-house radioimmu- ) was measured by its ability to convert benzylamine into benzaldehyde as described before. S3 Results from laboratory analyses are expressed as means± standard errors of the mean (s.e.m.). Differences in metabolic parameters between pioglitazone and placebo treatment were analysed with a paired t-test (95% confidence interval). In case of non-normal distribution, the Wilcoxon's signed-rank test was used. A P-value of less than 0.05 denotes a statistically significant difference.
All subjects completed the study. A summary of demographic, clinical and laboratory characteristics is shown in Supplementary Table 1. In Supplementary Table 2 , the effects of pioglitazone are summarized, as published previously. 7, 8 There were no appreciable carryover effects. As expected, pioglitazone treatment decreased plasma insulin levels, free fatty acids, adiponectin and C-reactive protein.
Pioglitazone treatment non-significantly reduced fasting blood glucose but did not lower HbA 1 c. In Table 1 , the plasma levels of vasoactive hormones and peptides are shown. We present the levels after the subjects have been on placebo for 4 weeks and after they have been 4 weeks on pioglitazone treatment. The difference between treatments is presented as D (concentration after pioglitazone treatment)À(concentration after 4 weeks placebo). No clinical relevant or statistical significant differences in plasma concentrations of any of the vasoactive hormones or peptides were observed after pioglitazone compared with placebo treatment.
Thiazolidinediones in general and pioglitazone in particular have been associated with ancillary, beneficial pleiotropic effects on the vasculature. Patients carrying a dominant-negative mutation in their PPAR-g gene develop severe early onset hypertension, 9 suggesting that PPAR-g indeed upholds normotension. In experimental studies, PPAR-g has been associated with a decrease in BP. 2, 3 In largescale clinical trials (PROactive 4 and RECORD 5 ) a slight but significant decrease in BP was observed.
However there are no data from trials on the levels of circulating vasoactive hormones/peptides in human subjects receiving TZD treatment. Therefore we evaluated the effects of pioglitazone on vasoactive hormones in patients with T2Dm in a wellcontrolled trial.
We measured several components of the reninangiotensin system (RAS) as PPAR-g, like other nuclear hormone receptors, transcriptionally regulates the RAS. 10 There is ample evidence from in vitro and animal studies to suggest that PPAR-g inhibits angiotensin II signalling. Conversely, PPARg is a positive regulator of renin transcription. Lansang et al.
11 studied the effects of rosiglitazone in T2DM subjects and reported no effects on PRA. In healthy volunteers, pioglitazone treatment was found to be associated with increased PRA and this was suggested to underpin the development of oedema in some subjects treated with TZD. 12 In the present study, we report that 4 weeks of treatment with pioglitazone does not affect circulating levels of PRA, prorenin, angiotensin II or aldosterone in human subjects with T2DM.
There are only limited data on the effects of pioglitazone on BNP levels. Cardiac fibroblasts release less BNP upon stretch when co-incubated with pioglitazone and in a hypertensive rat model pioglitazone reduced the cardiac expression levels of BNP, independent from BP. In contrast, in small clinical studies in people with T2DM, the use of pioglitazone resulted in significant increases in plasma (NT-pro) BNP levels in about half of the patients. In our study, no changes in NTproBNP and ANP were observed. Transcription and release of endothelin from cultured cardiomyocytes and endothelial cells is inhibited in vitro by pioglitazone. In a rat model of hypertension, rosiglitazone abrogated the increase in endothelin expression. Again, few data are available on the effects of pioglitazone in humans, and previous data are in concert with our findings. Overall, pioglitazone does not seem to affect endothelin levels in vivo. SSAO is a multi-functional enzyme widely present in nature. SSAO seems to have a role in atherogenesis, glucose regulation and leukocyte extravasation at inflammation sites, and plasma SSAO is elevated in diabetes mellitus, heart failure and liver cirrhosis. From this study, we do not detect a role of PPAR-g on SSAO, as pioglitazone treatment left SSAO unaltered.
In conclusion, we evaluated the effect of pioglitazone on the levels of circulating vasoactive hormones and peptides in patients with T2DM. We report that pioglitazone did not affect plasma concentrations of several vasoactive hormones and peptides. This does not exclude a vasoactive role of pioglitazone, but such an effect is unlikely to be mediated by direct effects of the vasoactive hormones and peptides examined in this study.
